1. Home
  2. HUMA vs VYGR Comparison

HUMA vs VYGR Comparison

Compare HUMA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Humacyte Inc.

HUMA

Humacyte Inc.

HOLD

Current Price

$0.68

Market Cap

185.4M

Sector

Health Care

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.94

Market Cap

194.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUMA
VYGR
Founded
2004
2013
Country
United States
United States
Employees
220
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.4M
194.0M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
HUMA
VYGR
Price
$0.68
$3.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
3
Target Price
$9.29
$21.00
AVG Volume (30 Days)
8.0M
879.5K
Earning Date
03-27-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,135,000.00
Revenue This Year
N/A
$33.19
Revenue Next Year
$731.05
$14.68
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$2.65
52 Week High
$2.93
$5.55

Technical Indicators

Market Signals
Indicator
HUMA
VYGR
Relative Strength Index (RSI) 31.26 48.26
Support Level N/A $3.61
Resistance Level $1.30 $4.43
Average True Range (ATR) 0.10 0.31
MACD -0.04 -0.04
Stochastic Oscillator 2.03 20.16

Price Performance

Historical Comparison
HUMA
VYGR

About HUMA Humacyte Inc.

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Share on Social Networks: